LLY$1,170.14

Lilly does not benefit from a true network effect in the way a digital platform or payments ecosystem does. Demand for its medicines does not become intrinsically more valuable simply because more patients use them. There is some soft ecosystem reinforcement: as more clinicians gain experience with Mounjaro, Zepbound, Verzenio, and Kisunla, prescribing familiarity rises, and payer familiarity can improve access. But that is not self-reinforcing in a structural sense, and competitors can replicate the same pattern after launch. Patients also multi-home across therapies, and the rise of compounded GLP-1s shows that usage volume does not create exclusive network value. Lilly’s advantage comes from science, not from participant-to-participant effects.

Switching costs are meaningful because many of Lilly’s core therapies are used in chronic, physician-managed settings where changing drugs creates clinical friction. Tirzepatide patients often need dose titration, side-effect monitoring, and insurance re-authorization, while providers must weigh efficacy, tolerability, and adherence history before switching. Oncology products such as Verzenio can be even stickier because treatment choices are embedded in care pathways and biomarker-driven regimens. That said, the category is not locked in: patients can move to semaglutide-based drugs, other diabetes therapies, or alternative oncology protocols if efficacy, coverage, or tolerability shifts. Lilly’s switching-cost advantage is real, but it is behavioral and administrative rather than absolute.

This is Lilly’s strongest pillar. The company has a powerful combination of FDA approvals, patent protection, clinical evidence, and trusted brands that are difficult for rivals to replicate quickly. Tirzepatide, Verzenio, Taltz, Kisunla, and legacy insulin lines each rest on substantial regulatory and scientific barriers, and the company has repeatedly shown it can convert research into commercially meaningful products. Lilly also has manufacturing know-how and formulation expertise that matter in peptides, antibodies, and biologics. The weakness is that these protections are time-limited, and history shows blockbuster franchises eventually face erosion. Even so, the breadth of Lilly’s portfolio and the depth of its clinical data make this a top-tier intangible asset base.

Lilly enjoys a meaningful but not unassailable cost advantage from its manufacturing scale, process know-how, and supply-chain depth. Building peptide and biologics capacity is capital intensive, and Lilly’s ability to ramp production of tirzepatide and other complex medicines gives it leverage that smaller rivals cannot easily match. Its global footprint also supports procurement, distribution, and quality-control efficiencies. However, this is not a permanent low-cost structure. Well-funded competitors can invest in similar facilities, and contract manufacturers can narrow the gap over time. In pharma, pricing power and rebate economics often matter more than pure manufacturing cost, so Lilly’s advantage is visible, but not decisive enough to qualify as exceptional.

Lilly operates in markets that are large enough to support several major competitors, so this is not a natural monopoly. However, in obesity and diabetes, the market has lately behaved like a tight oligopoly because regulatory approval, clinical evidence, manufacturing capacity, and payer access create very high entry barriers. That dynamic helps Lilly today, especially as capacity constraints limit how quickly smaller entrants can matter. Still, serious rivals remain, most notably Novo Nordisk, and major pharma companies can attack adjacent indications through their own pipelines. In oncology and immunology, the field is also crowded with capable incumbents. The structure supports scale benefits, but not the kind of protected scarcity associated with a truly wide moat.